OMCL vs. XNCR, SYRE, MORF, SLNO, PCRX, ESTA, DVAX, TARS, ALHC, and NMRA
Should you be buying Omnicell stock or one of its competitors? The main competitors of Omnicell include Xencor (XNCR), Spyre Therapeutics (SYRE), Morphic (MORF), Soleno Therapeutics (SLNO), Pacira BioSciences (PCRX), Establishment Labs (ESTA), Dynavax Technologies (DVAX), Tarsus Pharmaceuticals (TARS), Alignment Healthcare (ALHC), and Neumora Therapeutics (NMRA). These companies are all part of the "medical" sector.
Xencor (NASDAQ:XNCR) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
Omnicell has a net margin of -1.91% compared to Omnicell's net margin of -82.23%. Xencor's return on equity of 2.41% beat Omnicell's return on equity.
Xencor has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.
In the previous week, Omnicell had 5 more articles in the media than Xencor. MarketBeat recorded 10 mentions for Omnicell and 5 mentions for Xencor. Omnicell's average media sentiment score of 1.68 beat Xencor's score of 1.35 indicating that Xencor is being referred to more favorably in the media.
Omnicell has higher revenue and earnings than Xencor. Omnicell is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks.
Xencor currently has a consensus price target of $35.43, indicating a potential upside of 50.95%. Omnicell has a consensus price target of $42.20, indicating a potential upside of 30.61%. Given Omnicell's stronger consensus rating and higher possible upside, equities analysts clearly believe Xencor is more favorable than Omnicell.
Xencor received 1 more outperform votes than Omnicell when rated by MarketBeat users. Likewise, 72.89% of users gave Xencor an outperform vote while only 67.82% of users gave Omnicell an outperform vote.
97.7% of Omnicell shares are owned by institutional investors. 5.2% of Xencor shares are owned by company insiders. Comparatively, 2.6% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Xencor beats Omnicell on 9 of the 17 factors compared between the two stocks.
Get Omnicell News Delivered to You Automatically
Sign up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Omnicell Competitors List
Related Companies and Tools
